All In Biotech

Drug Trial Radar · NCT06667960

Study of JK06 in Patients With Unresectable Locally Advanced or Metastatic Cancer

A Phase 1/2, Multicenter, Open Label, Dose Escalation & Dose Expansion Study of JK06, a 5T4 Antibody Drug Conjugate, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Last checked: Nov 19, 2026Latest source record: Mar 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 255 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

255

Planned (sponsor's estimate)

Start

Oct 23, 2024

Primary completion

Apr 1, 2028

Study completion Aug 1, 2028

Sponsor

Lead sponsor
Salubris Biotherapeutics IncIndustry
Sponsor type
Industry
First posted
Oct 31, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1/2, open-label, multi-center, first-in-human, dose escalation and cohort expansion study evaluating multiple doses and schedules of intravenously administered JK06 in patients with unresectable locally, advanced or metastatic cancer.

Conditions

  • Solid Tumor

Interventions

  • JK06Drug

    Biparatopic anti-5T4 antibody

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-limiting Toxicity (DLT)Time frame: First 21 days of treatment.
  2. Dose-FindingTime frame: From First Patient Dosed to end of Escalation, up to 14 months.
  3. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]Time frame: First treatment through 28 days after last dose of treatment or End of Treatment [EOT] visit, whichever is later.
  4. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]Time frame: Screening date through 28 days after last dose of treatment or End of Treatment [EOT] visit, whichever is later.
  5. Objective Response Rate (ORR)Time frame: From date of randomization until the date of first documented progression, assessed up to 104 weeks

Locations

14 sites in 2 countries. Site status is shown where the registry gives one.

  • Universitair Ziekenhuis Antwerpen

    Antwerp, Belgium · Recruiting

  • Institut Jules Bordet

    Brussels, Belgium · Recruiting

  • UZ Ghent

    Ghent, Belgium · Recruiting

  • CHU UCL Namur - site Godinne

    Yvoir, Belgium · Recruiting

  • NEXT Oncology Barcelona

    Barcelona, Spain · Recruiting

  • START Barcelona

    Barcelona, Spain · Recruiting

  • Vall d Hebron Institute of Oncology VHIO

    Barcelona, Spain · Recruiting

  • CUN Madrid

    Madrid, Spain · Recruiting

  • October 12th Hospital

    Madrid, Spain · Recruiting

  • Next Oncology Madrid

    Madrid, Spain · Recruiting

  • START Madrid

    Madrid, Spain · Recruiting

  • CUN Pamplona

    Pamplona, Spain · Recruiting

  • START Rioja

    Rioja, Spain · Recruiting

  • Instituto de Investigación Sanitaria INCLIVA

    Valencia, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.